Show notes
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S.
Transcript
Transcript not available for this episode yet.
More from The Top Line
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min
Why modern clinical trials need a finance-first strategy (Sponsored)
Jul 20, 202617 min
5 emerging biotech hubs
Jul 17, 202624 min
Decision readiness is the next AI advantage (Sponsored)
Jul 13, 202618 min
The deal before the deal
Jun 26, 202641 min